BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells $582,067.42 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 25,687 shares of the firm’s stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total value of $582,067.42. Following the completion of the sale, the chief financial officer now owns 189,242 shares of the company’s stock, valued at approximately $4,288,223.72. This represents a 11.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, March 11th, Troy Wichterman sold 4,151 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total transaction of $103,775.00.
• On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The stock was sold at an average price of $25.46, for a total transaction of $16,803.60.
• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total transaction of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $26,668.74.

BioLife Solutions Trading Down 7.0 %

NASDAQ BLFS opened at $20.88 on Friday. The company’s 50-day simple moving average is $25.87 and its two-hundred day simple moving average is $25.48. BioLife Solutions, Inc. has a one year low of $14.84 and a one year high of $29.55. The company has a market capitalization of $981.36 million, a price-to-earnings ratio of -19.70 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. The company had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the previous year, the firm posted ($0.21) earnings per share. Equities analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On BioLife Solutions

A number of institutional investors have recently added to or reduced their stakes in the stock. D.A. Davidson & CO. raised its holdings in BioLife Solutions by 1.3% in the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock worth $1,069,000 after purchasing an additional 519 shares in the last quarter. Stifel Financial Corp raised its stake in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after acquiring an additional 670 shares in the last quarter. 1620 Investment Advisors Inc. lifted its position in BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 675 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in BioLife Solutions by 27.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock valued at $117,000 after acquiring an additional 950 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC acquired a new stake in BioLife Solutions in the fourth quarter valued at approximately $26,000. Institutional investors own 93.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. KeyCorp boosted their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. HC Wainwright boosted their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Benchmark reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. StockNews.com cut shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research report on Monday, March 31st. Finally, Northland Securities raised their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, BioLife Solutions has a consensus rating of “Moderate Buy” and an average target price of $31.17.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.